Cyclophosphamide
Evidence-based neurology checklist on cyclophosphamide: Dosing The intravenous regime is administered in weekly or monthly pulses The oral regime is administered qid The intravenous route has less toxicity Precautions Contraindications Monitoring Adverse events Indications for stopping
Dosing
- The intravenous regime is administered in weekly or monthly pulses
- The oral regime is administered qid
- The intravenous route has less toxicity
Precautions
Contraindications
Monitoring
Adverse events
Indications for stopping
References
- Amato AA, Russell JA. Neuromuscular Disorders. McGraw Hill New York 2008 p711.
- Teles KA, Medeiros-Souza P, Lima FAC, Araújo BG, Lima RAC. Cyclophosphamide administration routine in autoimmune rheumatic diseases: a review. Rev Bras Reumatol Engl Ed 2017; 57:596-604.
- Lapraik C, Watts R, Bacon P, et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology 2007; 46: 1615-1616.
- Malpica L, Moll S. Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases. Hematology Am Soc Hematol Educ Program 2020; 2020:319-327.
- Abrantes FF, Moraes MPM, Albuquerque Filho JMV, et al. Immunosuppressors and immunomodulators in Neurology - Part I: a guide for management of patients underimmunotherapy. Arq Neuropsiquiatr 2021; 79:1012-1025.
- And 1 more. Subscribe to see the full list
